Spots Global Cancer Trial Database for A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma
Official Title: Observational, Non-interventional, Multicenter Study Aimed at Collecting Prospective Data Related to Study Safety and Effectiveness in Real Clinical Practice in Patients With CD30+ Lymphoma (BRAVE Study)
Study ID: NCT04837222
Conditions
Interventions
Study Description
Brief Summary: Participants with CD30-positive lympoma will be treated with brentuximab vedotin according to their clinic's standard practice. The main aim of this study is to collect information on any side effects from treatment with brentuximab vedotin. Other aims are to collect information on how brentuximab vedotin is used to treat these participants and the outcomes of these participants.
Detailed Description: This is an observational, non-interventional, prospective study in participants with CD30-positive lymphoma who are receiving or will receive the standard treatment of brentuximab vedotin. This study will assess the safety profile and effectiveness of brentuximab vedotin in the real-world clinical practice. The study will enroll approximately 1000 participants. The data will be collected and recorded in the medical record for the purpose of medical care and also recorded in electronic case report forms (e-CRFs). All the participants will be assigned to a single observational cohort: ⢠All participants with CD30-positive lymphoma This multi-center trial will be conducted in China. All participants will be followed up for 24 months unless withdrawal of Informed Consent, lost or death, whichever comes first. The overall duration of the study will be approximately 4 years.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Peking University People's Hospital, Beijing, Beijing, China
Peking University Third Hospita, Beijing, Beijing, China
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
ZhuJiang Hosptital of Southern Medical University, Guangzhou, Guangdong, China
Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
HenanProvincial CancerHospital, Zhengzhou, Henan, China
Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
Zhongda Hospital Southeast University, Nanjing, Jiangsu, China
Jiangsu Province Hospital, Nanjing, Jiangsu, China
Affiliated Hodpital of Nantong University, Nantong, Jiangsu, China
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
The first hospital of Jilin University, Changchun, Jilin, China
The Second Hospital of Dalian Medical University, Dalian, Liaoning, China
Qilu Hospital of Shandong University, Jinan, Shandong, China
ShandongProvincial CancerHospital, Jinan, Shandong, China
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
ShanxiProvincial CancerHospital, Taiyuan, Shanxi, China
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Hematology Hospital of Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
Tianjin People's Hospital, Tianjin, Tianjin, China
Yunnan First People's Hospital, Kunming, Yunnan, China
The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China
Contact Details
Name: Study Director
Affiliation: Takeda
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
